Guidelines on the recognition of pain, distress and discomfort in experimental animals and an hypothesis for assessment

Under the 1876 Cruelty to Animals Act it is necessary to recognise pain so that an assessment may be made to determine if it is 'an experiment calculated to give pain' and 'to prevent the animal feeling pain'. Under the conditions of the licence it is also necessary to recognise 'severe pain which is likely to endure' and 'suffering considerable pain'. In the White Paper May 1983 (Command 8883) it is stated that: 'in the application of controls the concept of pain should be applied in a wide sense' and 'the Home Secretary's practice has been to interpret the concept of pain to include disease, other disturbances of normal health, adverse change in physiology, discomfort and distress'. The draft European Convention for the Protection of Vertebrate Animals used for Experimental and other Purposes, aims to control, subject to specific exceptions, any experimental or other scientific procedure which 'may cause pain, suffering, distress or lasting harm'. (The White Paper states that UK control will be stricter than the Council of Europe proposals.) Thus, there is a considerable onus on the experimenter to recognise pain (not to define it) and to alleviate it. It is intended that this article should be of help, not only to newcomers inexperienced in the recognition of pain, but also possibly to those relatively experienced workers who may be called upon to evaluate the pain involved in a new model or an individual animal.(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				S J Henare, D J Mellor, R G Lentle, and P J Moughan An appraisal of the strengths and weaknesses of newborn and juvenile rat models for researching gastrointestinal development Lab Anim, July 1, 2008; 42(3): 231 - 245. [Abstract] [Full Text] [PDF]

				J. C. Murrell, E. P. Psatha, E. M. Scott, J. Reid, and L. J. Hellebrekers Application of a modified form of the Glasgow pain scale in a veterinary teaching centre in the Netherlands Vet Rec., March 29, 2008; 162(13): 403 - 408. [Abstract] [Full Text] [PDF]

				R. J. Mairs, S. C. Ross, A. G. McCluskey, and M. Boyd A Transfectant Mosaic Xenograft Model for Evaluation of Targeted Radiotherapy in Combination with Gene Therapy In Vivo J. Nucl. Med., September 1, 2007; 48(9): 1519 - 1526. [Abstract] [Full Text] [PDF]

				A. G. McCluskey, M. Boyd, S. C. Ross, E. Cosimo, A. M. Clark, W. J. Angerson, M. N. Gaze, and R. J. Mairs [131I]meta-Iodobenzylguanidine and Topotecan Combination Treatment of Tumors Expressing the Noradrenaline Transporter Clin. Cancer Res., November 1, 2005; 11(21): 7929 - 7937. [Abstract] [Full Text] [PDF]

				M. Sadowski, J. Pankiewicz, H. Scholtzova, J. A. Ripellino, Y. Li, S. D. Schmidt, P. M. Mathews, J. D. Fryer, D. M. Holtzman, E. M. Sigurdsson, et al. A Synthetic Peptide Blocking the Apolipoprotein E/{beta}-Amyloid Binding Mitigates {beta}-Amyloid Toxicity and Fibril Formation in Vitro and Reduces {beta}-Amyloid Plaques in Transgenic Mice Am. J. Pathol., September 1, 2004; 165(3): 937 - 948. [Abstract] [Full Text] [PDF]

				R. A. Hirst, B. Gosai, A. Rutman, P. W. Andrew, and C. O'Callaghan Streptococcus pneumoniae Damages the Ciliated Ependyma of the Brain during Meningitis Infect. Immun., October 1, 2003; 71(10): 6095 - 6100. [Abstract] [Full Text] [PDF]

				A. Iwata, V. M. Stevenson, A. Minard, M. Tasch, J. Tupper, E. Lagasse, I. Weissman, J. M. Harlan, and R. K. Winn Over-Expression of Bcl-2 Provides Protection in Septic Mice by a trans Effect J. Immunol., September 15, 2003; 171(6): 3136 - 3141. [Abstract] [Full Text] [PDF]

				J. A. Plumb, P. W. Finn, R. J. Williams, M. J. Bandara, M. R. Romero, C. J. Watkins, N. B. La Thangue, and R. Brown Pharmacodynamic Response and Inhibition of Growth of Human Tumor Xenografts by the Novel Histone Deacetylase Inhibitor PXD101 Mol. Cancer Ther., August 1, 2003; 2(8): 721 - 728. [Abstract] [Full Text] [PDF]

				D. Le Bars, M. Gozariu, and S. W. Cadden Animal Models of Nociception Pharmacol. Rev., December 1, 2001; 53(4): 597 - 652. [Abstract] [Full Text] [PDF]

				N. A. Gingles, J. E. Alexander, A. Kadioglu, P. W. Andrew, A. Kerr, T. J. Mitchell, E. Hopes, P. Denny, S. Brown, H. B. Jones, et al. Role of Genetic Resistance in Invasive Pneumococcal Infection: Identification and Study of Susceptibility and Resistance in Inbred Mouse Strains Infect. Immun., January 1, 2001; 69(1): 426 - 434. [Abstract] [Full Text] [PDF]

				R.J. Fielder, J.A. Allen, A.R. Boobis, P.A. Botham, J. Doe, D.J. Esdaile, D.G. Gatehouse, G. Hodson-Walker, D.B. Morton, D.J. Kirkland, et al. Report of the BTS/UKEMS Working Group on Dose Setting in In-Vivo Mutagenicity Assays Human and Experimental Toxicology, January 1, 1993; 12(3): 189 - 198. [Abstract] [PDF]

				R.H. Inns and P. Rice Efficacy of Dimercapto Chelatin Agents for the Treatment of Poisoning by Percutaneously Applied Dichloro(2-chlorovinyl)arsine in Rabbits Human and Experimental Toxicology, January 1, 1993; 12(3): 241 - 246. [Abstract] [PDF]